Adherex Technologies (FENC) Projected to Post Quarterly Earnings on Tuesday

Key Points

• Adherex Technologies is set to announce its Q2 2025 earnings results on August 12th, with expectations of a loss of ($0.06) per share and revenue of $9.52 million.
• The company's stock recently traded down 4.1% to $7.98, with a market capitalization of $221.29 million.
• Analysts have upgraded Adherex Technologies to a "buy" rating, with a price target of $13.00, following positive earnings reports and insider stock movements.

Adherex Technologies (NASDAQ:FENC - Get Free Report) is projected to release its Q2 2025 earnings data before the market opens on Tuesday, August 12th. Analysts expect Adherex Technologies to post earnings of ($0.06) per share and revenue of $9.52 million for the quarter.

Adherex Technologies (NASDAQ:FENC - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.08. The business had revenue of $8.51 million during the quarter, compared to analyst estimates of $8.18 million. During the same quarter last year, the firm earned $0.41 EPS. On average, analysts expect Adherex Technologies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Adherex Technologies Price Performance

Adherex Technologies stock traded up $0.26 during midday trading on Friday, hitting $8.33. The company's stock had a trading volume of 40,739 shares, compared to its average volume of 51,738. Adherex Technologies has a 1-year low of $3.96 and a 1-year high of $9.30. The company has a 50-day moving average price of $8.35 and a two-hundred day moving average price of $7.07. The company has a market cap of $231.66 million, a price-to-earnings ratio of -16.33 and a beta of 0.40.

Insiders Place Their Bets

In other news, Director Rosty Raykov sold 10,000 shares of the company's stock in a transaction on Tuesday, August 5th. The shares were sold at an average price of $8.09, for a total value of $80,900.00. Following the sale, the director directly owned 55,878 shares of the company's stock, valued at approximately $452,053.02. This represents a 15.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Jeffrey S. Hackman bought 13,965 shares of the company's stock in a transaction that occurred on Monday, May 19th. The shares were bought at an average price of $6.99 per share, for a total transaction of $97,615.35. Following the transaction, the chief executive officer directly owned 15,000 shares in the company, valued at $104,850. This trade represents a 1,349.28% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 31,119 shares of company stock worth $254,546. Insiders own 11.76% of the company's stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Adherex Technologies stock. Jane Street Group LLC bought a new stake in shares of Adherex Technologies Inc. (NASDAQ:FENC - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 14,718 shares of the company's stock, valued at approximately $90,000. Jane Street Group LLC owned 0.05% of Adherex Technologies as of its most recent SEC filing. 55.51% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the stock. Wall Street Zen lowered shares of Adherex Technologies from a "buy" rating to a "hold" rating in a report on Saturday. HC Wainwright reissued a "buy" rating and set a $13.00 target price on shares of Adherex Technologies in a report on Tuesday, May 20th. Finally, Craig Hallum upped their price objective on shares of Adherex Technologies from $12.00 to $13.00 and gave the company a "buy" rating in a research note on Wednesday, May 14th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $13.00.

Adherex Technologies Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.